Literature DB >> 9862338

Parasite dose determines the Th1/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite.

J N Menon1, P A Bretscher.   

Abstract

Leishmania major causes cutaneous leishmaniasis in mice and man. Infection of mice with relatively low or high numbers of parasites leads respectively to parasite containment, associated with a Th1, cell-mediated response, or progressive disease, associated with a Th2, antibody response in all circumstances studied. These include different parasite strains, different routes of infection, and different hosts previously classified as susceptible, resistant or of intermediate susceptibility. This dose dependency appears to reflect a general rule. We argue that this rule may allow the design of a vaccination strategy that is effective among a genetically diverse population, and that it imposes severe constraints upon proposals for the nature of the "decision criterion" determining whether antigen induces a Th1 or Th2 response.

Entities:  

Mesh:

Year:  1998        PMID: 9862338     DOI: 10.1002/(SICI)1521-4141(199812)28:12<4020::AID-IMMU4020>3.0.CO;2-3

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  34 in total

1.  Evolution of lesion formation, parasitic load, immune response, and reservoir potential in C57BL/6 mice following high- and low-dose challenge with Leishmania major.

Authors:  R Lira; M Doherty; G Modi; D Sacks
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  The probability of severe disease in zoonotic and commensal infections.

Authors:  S A Frank; J S Jeffrey
Journal:  Proc Biol Sci       Date:  2001-01-07       Impact factor: 5.349

3.  Effect of low-dose antigen exposure on development of immunity to Helicobacter pylori infection in mice.

Authors:  F J Radcliff; R L Ferrero
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route.

Authors:  C A Power; G Wei; P A Bretscher
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

5.  Site-dependent recruitment of inflammatory cells determines the effective dose of Leishmania major.

Authors:  Flavia L Ribeiro-Gomes; Eric Henrique Roma; Matheus B H Carneiro; Nicole A Doria; David L Sacks; Nathan C Peters
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

6.  Evaluation of s.c. route of immunization by homologous radio attenuated live vaccine in experimental murine model of visceral leishmaniasis.

Authors:  Sanchita Datta; Supriya Khanra; Anindita Chakraborty; Syamal Roy; Madhumita Manna
Journal:  J Parasit Dis       Date:  2014-09-20

7.  Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.

Authors:  Khaled S Tabbara; Nathan C Peters; Farhat Afrin; Susana Mendez; Sylvie Bertholet; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major.

Authors:  Kazuo Yamakami; Shinkichi Akao; Takushi Tadakuma; Yoshio Nitta; Jyun-Ichi Miyazaki; Nobuyuki Yoshizawa
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

9.  Influence of parasite load on the ability of type 1 T cells to control Leishmania major infection.

Authors:  Brian Hondowicz; Phillip Scott
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

10.  Neutrophil and eosinophil chemotactic factors in the excretory/secretory products of sheep abomasal nematode parasites: NCF and ECF in abomasal nematodes.

Authors:  Stefanie Reinhardt; Ian Scott; Heather V Simpson
Journal:  Parasitol Res       Date:  2011-03-19       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.